Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2023-11-09 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
关于部分限制性股票回购注销完成的公告
Transaction in Own Shares Classification · 100% confidence The document is an official announcement from a company regarding the completion of a repurchase and cancellation of restricted shares under a 2022 restricted stock incentive plan. It details the number of shares repurchased, the reduction in total share capital, the approval process by the board and shareholders, the repurchase price, funding source, and the impact on share capital structure. It also references legal and audit opinions related to the transaction. The document is not a financial report, earnings release, or management discussion, but rather a formal announcement of a share repurchase and capital reduction event. This fits the category of Transaction in Own Shares (POS), which covers company buybacks or cancellations of its own shares.
2023-11-09 Chinese
关于召开公司2023年第三次临时股东大会的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about the convening of the company's 2023 third extraordinary general meeting of shareholders, including meeting date, voting procedures, registration details, and proxy forms. It does not contain financial statements or results but rather logistical and procedural information about the shareholder meeting. The document length is 3608 characters, which is relatively short and focused on meeting notification and voting instructions. This fits the description of a notice or announcement related to a shareholder meeting rather than the meeting materials or results themselves. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the meeting and voting process, not the actual AGM materials or voting results.
2023-11-02 Chinese
关于吡拉西坦注射液获得药品补充申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a pharmaceutical company about receiving approval from the National Medical Products Administration for a drug supplement application. It details the drug name, approval content, regulatory references, and impact on the company. The document is short (1171 characters) and is an announcement of regulatory approval rather than a financial report or detailed corporate filing. It does not contain financial data, management changes, voting results, or other report types. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about drug approval and related company impact.
2023-10-31 Chinese
关于高级管理人员减持股份计划期限届满未减持公司股份的公告
Director's Dealing Classification · 95% confidence The document is an announcement regarding a senior management personnel's shareholding reduction plan period expiration without actual share reduction. It includes details about the planned share reduction, confirmation that no shares were sold, and compliance with relevant regulations. The document is short (1368 characters) and serves as a formal disclosure of insider shareholding activity, specifically about a management member's shareholding transaction plan and its outcome. This fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives. There is no financial data or report content, so it is not an Annual Report or Earnings Release. It is not a general regulatory filing or announcement of a report publication. Therefore, the correct classification is DIRS with high confidence.
2023-10-26 Chinese
2023年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "东北制药集团股份有限公司2023 年第三季度报告" which translates to "Northeast Pharmaceutical Group Co., Ltd. 2023 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial metrics for the third quarter of 2023. The document explicitly states it is a quarterly report and is unaudited. The length of the document (12,241 characters) and the presence of comprehensive financial statements confirm it is a substantive financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2023
2023-10-26 Chinese
关于新增2023年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the addition of expected daily related-party transactions for the year 2023 by Dongbei Pharmaceutical Group Co., Ltd. It details the nature, amounts, and parties involved in these related-party transactions, including approvals by the board and independent directors. The document does not contain financial statements or comprehensive financial data but rather focuses on disclosure of related-party transaction estimates and approvals. It is a regulatory announcement about corporate governance and related-party dealings, not a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-10-24 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.